Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

- Republic of Georgia Drug Agency Approves Protocol for New Clinical Trial

of Bavituximab in Combination with Docetaxel -

TUSTIN, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in combination with the chemotherapy drug docetaxel in patients with metastatic breast cancer has been approved by the Drug Agency of the Ministry of Labour, Health and Social Affairs of Georgia. The open label, multi-center safety and efficacy trial is expected to begin enrolling patients by early 2008.

The primary objective of the trial is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in the treatment of metastatic breast cancer. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. In the trial's two-stage design, up to 15 patients with metastatic breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. The trial is expected to enroll patients at a minimum of three clinical trial sites.

"We are eager to assess bavituximab's potential in Phase II combination studies in a number of cancer indications, and we are very pleased to have received prompt regulatory approval to proceed with this breast cancer trial," said Steven W. King, president and CEO of Peregrine. "The clinical sites in the Republic of Georgia that will be par
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 The American Association of Poison ... centers are commending Senator Bill Nelson (D-FL) for his ... 2014 on July 10, 2014. Along with fellow Senate ... Commission (CPSC) to enact rules requiring safer, child-resistant packaging ... , Senate co-sponsors of the bill include: Sen. Richard ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... News) -- People with the lowest incomes may have a ... (PAD), a new study suggests. People with PAD have ... most often the legs. The condition causes leg pain and ... the body. People with PAD have a higher risk for ... 6,800 people with PAD who took part in the U.S. ...
(Date:7/11/2014)... 2014 Microbiology testing is a highly ... industry, which is expected to pose the biggest challenge ... owes its growth to the ongoing spread of AIDS ... and a major factor leading to the upsurge of ... and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3
... testing breast tumors for HER2 ( http://www.mayoclinic.com/health/breast-cancer/AN00495 ) proteins ... of tumor (a single tumor block) is analyzed. However, ... ( http://www.mayoclinic.org/ ) found that HER2 results can vary ... tumor blocks are analyzed. This could have significant ...
... News) -- Americans who live in walkable neighborhoods are ... a higher quality of life, a new study suggests. ... stroll to such destinations as parks and playgrounds, club ... coffee shops and restaurants, explained study author Shannon Rogers ...
... from a specialized scan, radiation oncologists at Mayo Clinic ... number of lymph nodes critical for removing fluid from ... VIDEO ALERT: Additional audio and video resources, including excerpts ... researchers presenting at San Antonio Breast Cancer Symposium, are ...
... GeparQuinto study, randomized Phase III efficacy data on the ... early breast cancer will be presented at the 33rd ... von Minckwitz, M.D., Ph.D., managing director of the German ... efficacy data from this study, which will detail the ...
... Dec. 10 (HealthDay News) -- Children and teens accounted for ... treated in U.S. emergency departments between 1997 and 2006, a ... such heat-related injuries also increased 133 percent during the study ... according to the researchers at the Center for Injury Research ...
... of circulating tumor cells (CTCs) cells that have detached ... the blood are an independent prognostic marker in metastatic ... CTC level during therapy was found to be an early ... series validating the prognostic value of CTCs in first-line chemotherapy ...
Cached Medicine News:Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 2Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 3Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 4Health News:'Walkable' Communities More Close-Knit, Study Finds 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 3Health News:Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented 2Health News:Children, Teens Account for Half of Exercise-Related Heat Injuries 2Health News:High CTC levels predicted poor outcome in metastatic breast cancer 2
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Pa., Sept. 9 DeVilbiss Healthcare has selected Business ... the successful implementation of its Microsoft Dynamics AX solution. ... Sunrise Medical, DeVilbiss sought to select and implement a ... successful medical device manufacturer. The primary ...
... Sept. 9 Diplomat Specialty Pharmacy announced today they have earned ... ranking of the fastest-growing private companies in America. "We,re ... earning a position of 554 in the nation, but if you ... are even more remarkable," stated Phil Hagerman, President and CEO of ...
Cached Medicine Technology:Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare 2Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: